Englewood Cliffs NJ, Dec. 14, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, announced the engagement of Donohoe Advisory Associates LLC (“Donohoe”) for consulting and advisory services in connection with the potential up-listing of Silo’s common shares on the NASDAQ Stock Market.


Previous articlePT277 – Ryan Zurrer – Venture Capital, Reciprocity, and the Regenerative Financing Vine
Next articleEditor’s Choice Award 2021-Best Study on Psychedelics and Neuroplasticity